Last reviewed · How we verify
NCT03501173: GURC
A Study of Participants With Advanced Prostate Cancer in Canada
trial testing Standard of Care in Prostatic Neoplasms in 374 participants. Completed in 14 July 2023.
14 July 2023
Quick facts
| Lead sponsor | Janssen Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 374 |
| Start date | 12 April 2018 |
| Primary completion | 14 July 2023 |
| Estimated completion | 14 July 2023 |
| Sites | 22 locations across Canada |
Drugs / interventions tested
- Standard of Care
Conditions studied
- Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Sponsor
Janssen Inc. — full company profile →
Who can join
21 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03501173
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard of Care
Trials testing the same drug.
- NCT07337655 — Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker · Phase 2, PHASE3 · not yet recruiting
- NCT07018466 — Tele-Exercise for MERP · NA · not yet recruiting
- NCT06930768 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers · NA · not yet recruiting
- NCT06918548 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Pressure Injuries · NA · not yet recruiting
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
Other recruiting trials for Prostatic Neoplasms
Currently open trials in the same condition.
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
- NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
- NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting
Other Janssen Inc. trials
Trials by the same sponsor.
- NCT03729349 — Golimumab for Adherence in Rheumatoid Arthritis · completed
- NCT02688075 — An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in · completed
- NCT02364531 — A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Sett · completed
- NCT01483599 — A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis · Phase 2 · completed
- NCT00741793 — Biologic Treatment Registry Across Canada · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03501173 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Inc.
- Last refreshed: 25 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03501173.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing